Mvondo Marie Alfrede, Wego Kamgaing Marius Trésor, Wansi Ngnokam Sylvie Léa
Department of Animal Biology, Faculty of Science, University of Dschang, Dschang, Cameroon.
J Complement Integr Med. 2021 Nov 11;20(3):566-576. doi: 10.1515/jcim-2021-0121. eCollection 2023 Sep 1.
Combining tamoxifen, the most common breast cancer hormonal therapy, with natural antitumor substances may prevent its hyperplastic effects on the uterine endometrium. () is traditionally recommended for the treatment of cancerous diseases. To investigate its antiproliferative properties, the present study was designed to assess the ability of the combined administration of tamoxifen with the aqueous extract of leaves to inhibit the trophic effect of this hormone therapy on rat uterine endometrium without compromising its non-proliferative effect on breast tissue.
Ovariectomized (OVX) female rats were simultaneously treated with tamoxifen (10 mg/kg) intraperitoneally and leaves (at doses of 25, 50 and 100 mg/kgBW) by gavage. Control groups received either distilled water or tamoxifen alone. Treatments lasted 37 days. The 38th day, animals were sacrificed under anesthesia (diazepam: 10 mg/kgBW and ketamine: 50 mg/kgBW). The relative uterine weight was determined and the histological analysis of the uterus and mammary gland was performed. The oxidative status of the uterus was assessed and the levels of cholesterol and estradiol were evaluated in serum and uterus.
Tamoxifen increased uterine weight and induced endometrial hyperplasia. This effect was associated with increased uterine levels of cholesterol (164.22%; p < 0.001), estradiol (927.5%; p < 0.001) and malondiadehyde (86%; p < 0.05), but unchanged antioxidant enzymes activities. The administration of leaves unchanged tamoxifen-increased uterine weight but reduced uterine epithelium hypertrophy (56.4%; p < 0.01). also increased uterine levels of malondiadehyde and antioxidant enzymes. The levels of estradiol and cholesterol in the uterus decreased while no changes were observed in the mammary gland of animals treated with tamoxifen alone or in co-administration with .
has antiproliferative properties and could complement endocrine therapy of estrogen-dependent breast cancer.
将最常见的乳腺癌激素疗法他莫昔芬与天然抗肿瘤物质联合使用，可能会预防其对子宫内膜的增生作用。（）传统上被推荐用于治疗癌症疾病。为了研究其抗增殖特性，本研究旨在评估他莫昔芬与叶水提取物联合给药抑制这种激素疗法对大鼠子宫内膜的营养作用的能力，同时不影响其对乳腺组织的非增殖作用。
对去卵巢（OVX）的雌性大鼠同时进行腹腔注射他莫昔芬（10mg/kg）和通过灌胃给予叶（剂量分别为25、50和100mg/kg体重）。对照组分别给予蒸馏水或单独给予他莫昔芬。治疗持续37天。在第38天，动物在麻醉下（地西泮：10mg/kg体重和氯胺酮：50mg/kg体重）处死。测定相对子宫重量，并对子宫和乳腺进行组织学分析。评估子宫的氧化状态，并测定血清和子宫中胆固醇和雌二醇的水平。
他莫昔芬增加了子宫重量并诱导了子宫内膜增生。这种作用与子宫中胆固醇水平升高（164.22%；p<0.001）、雌二醇水平升高（927.5%；p<0.001）和丙二醛水平升高（86%；p<0.05）相关，但抗氧化酶活性未改变。给予叶未改变他莫昔芬增加的子宫重量，但减少了子宫上皮肥大（56.4%；p<0.01）。叶还增加了子宫中丙二醛和抗氧化酶的水平。子宫中雌二醇和胆固醇水平降低，而单独给予他莫昔芬或与叶联合给药的动物乳腺中未观察到变化。
叶具有抗增殖特性，可作为雌激素依赖性乳腺癌内分泌治疗的补充。
